CardioNet, Inc. and AirStrip Partner to Expand Mobile Patient Monitoring

  CardioNet, Inc. and AirStrip Partner to Expand Mobile Patient Monitoring

  Integrated Mobility Solution Enables Health Systems to Improve Delivery of
                                 Cardiac Care

Business Wire

CONSHOHOCKEN, Pa. & SAN ANTONIO -- February 13, 2013

As health systems are under increasing pressure to share data across systems
to improve and expand their networks of care, CardioNet, Inc. and AirStrip
have entered into a partnership agreement to develop and co-market an
integrated solution for mobile patient monitoring.

The AirStrip^TM mobility solution will deliver live patient data from
CardioNet’s Mobile Cardiac Outpatient Telemetry^TM (MCOT^TM) directly to
clinicians’ mobile devices, including tablets and phones. This integrated
solution will enable health systems to combine critical cardiac data with EMR
and device information to improve patient monitoring and clinician
decision-making at the point of care.

“This partnership is the foundation for a powerful end-to-end cardiac care
package that promises to have a game-changing impact on 30-day readmissions
for heart failure,” said Alan Portela, AirStrip CEO. “Our pioneering mobility
solution delivers critical patient data to physicians anywhere across the care
continuum to encourage better decision-making and improve both the timeliness
and quality of care. This integration with CardioNet’s platform enables health
systems to empower clinicians with the information they need to achieve key
quality metrics in cardiology – one of the most resource and time-intensive
practice areas within healthcare.”

While details of the partnership agreement were not disclosed, it is exclusive
to select markets. The two companies expect to deliver a market-ready solution
by mid-year.

Joseph H. Capper, CardioNet’s President and CEO, commented: “This
collaboration is one of the most exciting initiatives CardioNet has embarked
on to date. As the leader in the mobile cardiac telemetry market, we are
always looking for avenues to expand the utilization of our data. The AirStrip
solution is the leading FDA-cleared technology for the transmission of
virtual, live ECG waveforms to a healthcare provider’s mobile device. This
solution is rapidly transforming the way clinical data is delivered and
integrated in a point of care setting. Incorporating the timely, accurate
information derived from MCOT^TM into AirStrip’s state-of-the-art mobile
system will undoubtedly improve the physician’s ability to deliver the proper
treatment, the first time.”

Tweet This: @AirStripmHealth and @CardioNetMCOT partner to enable mobile
patient monitoring in cardiac care

About CardioNet, Inc.

CardioNet is the leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely clinical
information regarding an individual’s health. CardioNet’s initial efforts are
focused on the diagnosis and monitoring of cardiac arrhythmias, or heart
rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient
Telemetry™ (MCOT™). Through its Cardiocore division, CardioNet is offers core
lab services to pharmaceutical and devise sponsors as they mover new products
through the development process. More information can be found at

About AirStrip

AirStrip ( provides healthcare’s only complete, vendor-
and data source-agnostic enterprise-wide clinical mobility solution, which
enables clinicians to improve the health of individuals and populations. With
deep clinical expertise and strong roots in mobile technology and data
integration, AirStrip is empowering the nation’s leading health systems as the
industry continues to evolve to new business models, accountable care and
shared risk. Based in San Antonio, Texas, AirStrip allows health systems to
unlock the full potential of their existing technology investments with a
complete mobility solution that provides access to critical patient data
across the care continuum. AirStrip is backed by investments from Sequoia
Capital, Qualcomm, Inc., Hospital Corporation of America (HCA) and the
Wellcome Trust.

Follow AirStrip

  *Twitter: @AirStripmHealth


This document includes certain forward-looking statements within the meaning
of the “Safe Harbor” provisions of the Private Securities Litigation Reform
Act of 1995 regarding, among other things, our growth prospects, the prospects
for our products and our confidence in the Company’s future. These statements
may be identified by words such as “expect,” “anticipate,” “estimate,”
“intend,” “plan,” “believe,” “promises” and other words and terms of similar
meaning. Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including important factors that
could delay, divert, or change any of these expectations, and could cause
actual outcomes and results to differ materially from current expectations.
These factors include, among other things, the effect of the Cardiocore
acquisition on our business operations and financial results and our ability
to successfully integrate its operations into our business, the national rate
set by the Centers for Medicare and Medicaid Services (“CMS”) for our mobile
cardiovascular telemetry service, effects of changes in health care
legislation, effectiveness of our cost savings initiatives, relationships with
our government and commercial payors, changes to insurance coverage and
reimbursement levels for our products, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive management
and sales personnel, our ability to identify acquisition candidates, acquire
them on attractive terms and integrate their operations into our business, our
ability to develop and co-market an integrated telemetry platform with
Airstrip Technologies, Inc., the commercialization of new products, market
factors, internal research and development initiatives, partnered research and
development initiatives, competitive product development, changes in
governmental regulations and legislation, the continued consolidation of
payors, acceptance of our new products and services, patent protection,
adverse regulatory action, and litigation success. For further details and a
discussion of these and other risks and uncertainties, please see our public
filings with the Securities and Exchange Commission, including our latest
periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise.


Chris Lato, 608-219-7231
Susan McCarron, 617-986-5767
CardioNet, Inc.
Heather C. Getz, 800-908-7103
Press spacebar to pause and continue. Press esc to stop.